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Abstract 
Obtaining informed consent (IC) is an ethical imperative, signifying participants’ understanding of 
the conditions and implications of research participation. One setting where the stakes for 
understanding are high is randomized controlled trials (RCTs), which test the effectiveness and 
safety of medical interventions. However, the use of legalese and medicalese in ethical forms 
coupled with the need to explain RCT-related concepts (e.g., randomization) can increase patients’ 
cognitive load when reading text. There is a need to systematically examine the language demands of 
IC documents, including whether the processes intended to safeguard patients by providing clear 
information might do the opposite through complex, inaccessible language. Therefore, the goal of 
this study is to build an open-access corpus of patient information sheets (PIS) and consent forms 
(CF) and analyze each genre using an interdisciplinary approach to capture multidimensional 
measures of language quality beyond traditional readability measures. A search of publicly-available 
online IC documents for UK-based cancer RCTs (2000-17) yielded corpora of 27 PIS and 23 CF. 
Textual analysis using the computational tool, Coh-Metrix, revealed different linguistic dimensions 
relating to the complexity of IC documents, particularly low word concreteness for PIS and low 
referential and deep cohesion for CF, although both had high narrativity. Key part-of-speech 
analyses using Wmatrix corpus software revealed a contrast between the overrepresentation of the 
pronoun ‘you’ plus modal verbs in PIS and ‘I’ in CF, exposing the contradiction inherent in 
conveying uncertainty to patients using tentative language in PIS while making them affirm certainty 
in their understanding in CF.  
 
Keywords: Cancer; Clinical trials; Corpus linguistics; Informed consent; Research ethics  
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Introduction 
Obtaining informed consent (IC) for research involving participants is an ethical imperative, 
legal requirement, and widely accepted international standard (World Medical Association, 2013). 
As a safeguard intended to protect human dignity, welfare, and rights, it necessitates adequate 
disclosure from investigators about research aims and procedures together with participants’ 
understanding of the conditions and implications of participation (Silva & Sorrell, 1984). After 
decades of research on IC, debates centring on fundamental considerations persist, including how 
much information participants should receive, what constitutes sufficient understanding (Grady, 
2015), and how to establish that participation decisions are an act of free will to a sufficient degree 
(Miller et al., 2009).  
One setting where the stakes for understanding are high in view of the potential consequences 
of research participation is clinical trials, which test the effectiveness and safety of new medical 
interventions for patients. Much of the IC literature, therefore, resides in the trials methodology 
research, including randomized controlled trials (RCTs), which are widely regarded as the most 
robust method for making causal inferences between an intervention and outcome in medicine 
(Cockayne et al., 2017). However, a perennial challenge is recruiting enough participants, with over 
half of RCTs failing to meet recruitment targets in some estimates, leading to statistically 
underpowered studies (Treweek et al., 2018b). Among the recruitment barriers, difficulties related to 
the IC process have been well-documented (Kearney et al., 2018). The biggest challenge with IC in 
clinical trials is how to provide meaningful information in a way that potential participants can 
understand and then use to make a decision about their participation in the study. 
Trialists face numerous challenges when communicating ethical information to patients. 
First, research ethics committees are charged with enforcing processes to protect patients, ensure 
regulatory compliance, and protect against liability (Beskow et al., 2010). Researchers’ efforts to 
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render IC documents less lengthy and complex are often stymied by ethics committees or project 
sponsors, presenting obstacles for researchers trying to improve the accessibility of their documents 
(Grady et al., 2017). Second, patients often have no medical training. Thus, medical concepts need to 
be explained using plain language, particularly for patients with low literacy, health literacy, or 
language proficiency (Peters et al., 2016). Third, methodological concepts regarding trial design 
(e.g., ‘trial arm,’ ‘placebo’) can be difficult to explain to stakeholders with little background in trials 
(Tam et al., 2015). Unlike the two aforementioned challenges, this challenge is trial-specific and 
further contributes to the complexity of the information to be conveyed, particularly for RCTs, due to 
the need to explain to participants why they are being randomized. But patients are not the only 
stakeholders who may be unfamiliar with trial design principles. Recruiters themselves vary in their 
understanding of trial research design features and, hence, in the information they are able to 
communicate to patients during recruitment consultations (Wade et al., 2017). In sum, trialists are 
charged with conveying complex specialist information during IC but face barriers to making the 
information accessible.  
Some nested RCTs have examined whether optimizing written IC documents enhances 
patient understanding and/or recruitment to the host RCT. For instance, Cockayne et al. (2017) 
compared a control PIS with one optimized version modelled on the National Research Ethics 
Service template, and another based on user testing and a graphic designer’s input. However, the PIS 
version that was used had no effect on recruitment. This null result is ambiguous. It could be that 
when IC is done well (i.e., renders the core information in an understandable and accessible way to 
prospective participants), this could increase participant recruitment. Conversely, if patients 
understand more about the conditions and potential repercussions of research participation, this could 
undermine recruitment efforts—a relationship that needs to be explored in further work but is 
beyond the scope of the present study. Grady et al. (2017) found that the use of a more concise, 
 
 
LANGUAGE DEMANDS OF INFORMED CONSENT IN TRIALS 
7 
 
simplified CF, compared to a control CF, neither impeded nor improved patients’ understanding of 
the purpose of randomization or satisfaction with the IC process. However, neither study 
systematically analyzed language use in the ethical documents beyond unidimensional measures of 
reading grade level. The current study addresses this gap by analyzing the written discourse of 
ethical documents, drawing on methods from corpus and computational linguistics to build an 
evidence base for improving their accessibility. 
Textual analysis in healthcare settings 
Textual analysis of medical English using corpus or computational tools, sometimes 
alongside qualitative methods, has been conducted using medical imaging reports (Friedman, 2000), 
discharge summaries (Friedman, 1997), medical abstracts (Nye et al., 2018), electronic records 
(Teufel & Elhadad, 2002), patient information pamphlets (Peters et al., 2016), patient accounts of 
their experiences (Semino et al., 2018), and patient feedback about health services (Baker et al., 
2019). However, textual analysis in trial recruitment research is in its infancy. Few studies have 
examined the linguistic properties of written IC documents used in trials, and those that do report 
limited measures such as wordcount and/or readability, which incorporates word and sentence length 
(e.g., Gillies et al., 2014, although see O’Sullivan et al., 2020, for a wider range of related indices). 
However, such measures fail to take into account the multicomponential nature of reading that 
language learning theories and research suggest is not restricted to lexical and syntactic processing, 
but also encompasses discourse- and semantic-level processing (Koda, 2005). For example, 
discourse markers and connectives (e.g., ‘but,’ ‘however’) provide information about how clauses, 
sentences, and paragraphs relate to one another, helping the reader grasp how ideas are bound 
together in extended text. However, the use of such cohesive cues negatively correlates with 
readability measures because the addition of extra words increases sentence length (McNamara et al., 
2014). This aspect of text difficulty has not been considered in trials research and best practice 
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guidelines for crafting ethical documents, which assume that reducing sentence length always 
improves comprehension (e.g., Health Research Authority, 2019).  
Furthermore, word count and readability measures are impervious to meaning. For example, 
words that are polysemous (i.e., have multiple meanings), such as ‘screening’ or ‘trial,’ and 
especially grammatical words that are both polysemous, and carry relatively little concrete meaning, 
such as markers of modality (e.g., ‘can,’ ‘might,’ ‘should’), can increase readers’ processing load 
compared to content words with only a single sense. The use of polysemous words compounds the 
challenge of extracting the correct meaning, particularly for patients accessing information in their 
nondominant language, potentially contributing to communication difficulties (Isaacs et. al., 2011). 
These examples illustrate that text difficulty cannot be adequately characterized using readability 
alone, which underrepresents the processing involved in reading text (McNamara et al., 2014). A 
wider array of linguistic measures is needed to capture different facets of text difficulty and language 
quality.  
In light of this research gap and driven by the need to build an evidence base on the language 
of IC, this mixed methods study draws on techniques from corpus and computational linguistics to 
investigate the language demands of written IC documents used for RCT recruitment. The goal is to 
describe the development of the first open-access online corpora of IC documents for RCTs (Isaacs 
et al., 2019). This is also the first study to systematically compare the linguistic properties of PIS and 
CF to one another and to two larger reference corpora to examine different facets of text difficulty 
and language quality by extracting multidimensional measures and analyzing grammatical function.  
Materials and methods 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 
(Moher et al., 2009) were used to select sources to include in our corpora using several criteria. First, 
we only included RCTs because explaining random allocation could increase language demands 
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(Nishimura et al., 2013). Second, we limited our search to RCTs in progress or completed after 2007, 
with the timeframe for inclusion January 2007 to July 2017. The UK Medicines for Human Use 
(Clinical Trials) Regulations came into law in 2004, in line with the EU Clinical Trials Directive 
(Bollapragada et al., 2007). Therefore, the trials included in our data search fall under this legislative 
regulation, which aligns with our goal of examining language use in ethical documents for 
contemporary cancer RCTs. Third, we confined our search to UK-based RCTs targeting any type of 
cancer for adult patients (≥ 18 years) who been diagnosed with cancer or were undertaking cancer 
screening or testing. Nested studies not directly testing cancer interventions and emergency 
interventions were excluded. We focused on cancer because it affects a wide cross-section of society 
and receives the largest proportion of UK research funding for any disease type (Medical Research 
Council, 2015). The expediency of using ‘cancer’ as a search term was another consideration, as we 
believed that the different types of cancer and interventions would contribute to the breadth of IC 
documents that we could access. This also enabled us to compile corpora that are sufficiently 
homogeneous to examine language complexity without interference from factors such as topic or 
language variety. Finally, for inclusion in our corpora, an English language PIS and/or CF needed to 
be publicly available online at the time of the data search.  
After consulting a medical librarian, we used the search terms ‘Randomised Controlled 
Trials’ AND ‘Cancer’ as a Health Research Classification System Category, a UK Clinical Research 
Collaboration Category, or keyword. Identified RCTs were screened against the inclusion criteria 
using the following e-repositories or databases: (1) National Institute for Health Research (NIHR) 
Journals Library, (2) Europe PubMed Central for RCTs funded by Cancer Research UK, Prostate 
Cancer UK, Academy of Medical Sciences, Breast Cancer Now, Breast Cancer Campaign, or 
Dunhill Medical Trust, (3) Research for Patient Benefit (RfPB) funded studies, (4) Medical Research 
 
 
LANGUAGE DEMANDS OF INFORMED CONSENT IN TRIALS 
10 
 
Council (MRC) funded studies, (5) Medline, (6) Embase, and (7) Cochrane Central Register of 
Controlled Trials.  
The search yielded a list of ongoing or completed studies or publications. We collected 
electronic records of initially eligible studies in a spreadsheet and screened abstracts using the 
inclusion criteria. In full-text screening, we manually reviewed the contents page, methods, 
appendixes, and supplementary files for IC documents, resolving any eligibility uncertainties through 
discussion. We searched the ISRCTN registry, clinical Trials.gov, and EU Clinical Trials Register 
for web links where ethical forms might be stored and performed free text searches for ‘consent,’ 
‘information sheet,’ and ‘information leaflet.’ Data saturation was then checked against the first 100 
Google Scholar entries and RCTs categorized under ‘cancer’ on the Online Resource for 
Recruitment research in Clinical triAls (ORRCA) database (Kearney et al., 2018). No new sources 
were identified, suggesting that data sources were exhausted. After removing duplicates, we 
uploaded citation information of included studies to Endnote X8 and recorded metadata about each 
associated RCT in a spreadsheet, including study start date, duration, research design information 
(individual/cluster RCT; number of study arms), patient blinding to the treatment group to which 
they were assigned, number of interventions and whether they were clinical (e.g., chemotherapy), 
behavioral (e.g., exercise regimen), or educational (e.g., dietary advice), cancer type(s), and reason 
for the study (e.g., screening). We also captured information about the ethical documents retrieved, 
including data source, translation availability, and presence of nontextual information (e.g., 
flowcharts, tables, other media/formats).  
To prepare the PIS and CF corpora for analysis and subsequent digital archiving, each file was 
converted to .txt format, corrected for spacing/hyphenation, and anonymized. The word ‘TABLE’, 
‘DIAGRAM,’ or ‘IMAGE’ was inserted in the place of tabular or graphical information. The files 
were then aggregated to create separate corpora for PIS and CF and deposited in the UK Data 
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Service’s open-source repository, ReShare, along with metadata (Isaacs et al., 2019; see online 
Supplementary Materials for further information about the search strategy and data preparation).  
Data Analysis 
The PIS and CF were analyzed separately because they comprise different functions—
information provision to help patients make a participation decision in the former, and confirmation 
that they have understood the conditions and consented to participate in the latter (Health Research 
Authority, 2019). Coh-Metrix 3.0 (2019), a computational tool extensively used in language 
research, was used to generate automated measures theorized to align with the processes, structures, 
and representations involved in processing text. We first report word count and Flesh-Kincaid grade 
level, a common readability measure, in line with previous trials methodology research. To provide a 
multidimensional view of textual quality, we report five of what the Coh-Metrix developers coined 
‘easability’ dimensions, hereafter referred to as text ease dimensions. These dimensions are the five 
principal components that an earlier Coh-Metrix validation study had revealed most robustly capture 
textual differences across text genre and pre-graded level (Graesser et al., 2011). Text ease is, 
therefore, operationalized here as the overall profile of the five following dimensions:  
1. Narrativity: The extent to which the text communicates a story, event, or procedure in 
conversational style. This dimension is underpinned by word familiarity and given 
information that links to readers’ prior knowledge. Notably, 17 Coh-Metrix measures in 
Graesser et al.’s validation study loaded onto the narrativity dimension (component 
score) as primary measures, contributing to its complex, multi-faceted nature. Narrativity 
was found to be the most robust dimension in accounting for differences between text 
genre and grade level. Informational texts about unfamiliar topics that do not resemble 
oral language would score low on this dimension. 
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2. Syntactic simplicity: The extent to which sentences are syntactically simple and easy to 
process. Long sentences with embedded clauses that place demands on readers’ working 
memory would score low on this dimension. 
3. Word concreteness: The extent to which content words in the text are concrete (i.e., have 
physical form) and imageable (i.e., invoke mental images). Texts laden with abstract 
concepts would score low on this dimension. 
4. Referential cohesion: The extent to which content words and ideas overlap across 
sentences and the whole text, enabling readers to draw interconnections between them. 
Texts with little overlap that do not show how different threads relate to one another 
would score low on this dimension. 
5. Deep cohesion: The extent to which the text contains the following categories of 
connectives to hold the text together: causal (e.g., ‘due to;’ ‘therefore’), temporal (e.g., 
‘during;’ ‘finally’), logical (e.g., ‘if,’ ‘therefore’), and additive (e.g., ‘in addition;’ 
‘furthermore’). Texts with few such connectives would score low on this dimension. 
It is beyond the scope of this article to describe how the measures comprising these 
dimensions were computed. Our purpose is simply to describe the dimensions so that the text ease 
profiles can be interpreted. We report Coh-Metrix indices in relation to the Touchstone Applied 
Science Associates (TASA) corpus, the most comprehensive corpus of graded US educational texts, 
which approximates average American college students’ textual exposure during their lifetime 
(Jones, 2006). Clearly, the purpose of PIS and CF is different than science texts; however, there are 
parallels in needing to explain sometimes technical information to a lay audience. There are no 
medical information texts written for patients, to our knowledge, that are benchmarked to school 
grade level and, hence, aligned to an expected reading or text difficulty level, making the TASA 
corpus the best available means of comparison. Previous health research has found that the 
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readability of ethical documents for patients far exceeds the average reading level of the average 
American, which is considered to be at or below eighth grade level (Eltorai et al., 2015). The 
American Medical Association (AMA) recommends that written health materials not exceed a sixth 
grade reading level (Weiss, 2003), whereas the National Institutes of Health (NIH) recommends 
maintaining a seventh to eight grade level (2017). This guidance made it meaningful to compare the 
PIS and CF corpora to the TASA science texts at levels approximating AMA and NIH 
recommendations (grades 6 to 8) and far exceeding it (grades 11+). We report text ease dimensions 
as mean percentiles, with higher scores implying less cognitive effort in processing the text.  
To complement these analyses, we used the web-based corpus tool, Wmatrix4 (Rayson, 
2008), which facilitates running automatic searches and drawing comparisons between electronic 
corpora, to determine the characteristic lexical and grammatical features of the IC documents, 
extracting examples from our corpora to illustrate language use. We compared the PIS and CF to a 
larger general written corpus, Baker’s (2009) million-word British English 2006 (BE06), to 
investigate differences in lexical frequency. BE06 represents the kind of language that an ‘average’ 
British-born speaker might use or encounter in general, making it useful for examining lexical and 
grammatical features that are overrepresented in PIS and CF compared to general written English. 
We interrogated the data for keywords, key parts-of-speech (POS), and concordances (see McEnery 
& Hardie, 2012), each of which we describe in the Results section  
Results 
The initial search yielded 863 records after removing duplicates, which were then screened 
for the inclusion criteria, resulting in 263 RCTs before the criterion of the availability of the PIS or 
CF online was applied. This resulted in a 62,030-word corpus of 27 PIS and an 8118-word corpus of 
23 CF drawn from 28 RCTs (see Figure 1). Twenty-six RCTs randomized patients at the individual 
level, whereas two were cluster RCTs (Davies et al., 2000; Kitchener et al., 2016). Patients were 
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aware of which treatment they would receive in 26 RCTs, with two blinding patients to the study 
arm (Langley et al., 2014; Stein et al., 2016). Clinical or procedural interventions were by far the 
most common (e.g., colonoscopy; Barr et al., 2009) and were a feature of 24 of the 28 RCTs. Eight 
of the 28 RCTs included at least one behavioral or educational intervention (e.g., healthy eating and 
physical activity program to promote behavior change; Koutoukidis et al., 2016). This was coupled 
with a clinical/procedural intervention in two studies (Davies et al., 2013; Halligan et al., 2015). 
Only Warde et al. (2012), which recruited patients from multiple countries, gave participants the 
option of IC documents in a language other than English. Table 1 summarizes further RCT 
characteristics. 
<FIGURE 1> 
<TABLE 1> 
The mean PIS wordcount was 2297.4 (SD = 1080.5) compared to 352.6 words for CF (SD = 
169.9). Eighteen of the 27 PIS were comprised solely of text, six included a trial design flowchart 
(Foxtrot Collaborative, 2012; Hamdy et al., 2015; Langley et al., 2014; Mulvenna et al., 2012; Stein 
et al., 2016; Woods et al., 2016), three featured tables of study visits or tests and procedures (Faivre-
Finn et al., 2016; Hamdy et al., 2015; James et al., 2016), and two included a diagram portraying the 
condition or intervention (Hamdy et al., 2015; Hill et al., 2016). Figure 2 shows keywords in PIS and 
CF compared to the BE06 corpus, that is, words that were overrepresented in our corpora compared 
to the larger reference corpus (BE06) based on log-likelihood (LL) to measure statistical significance 
(LL = 10.83, minimum raw frequency of 8, p < 0.001; Rayson et al., 2004). We used Log Ratio as an 
effect size measure and excluded any categories below 1.5, which roughly translates to a feature 
being more than twice as common in the PIS or CF corpus than in BE06 (Brezina, 2018). The 
enabled us to focus on the statistically significant categories that represent the largest differences 
between the corpora while retaining a manageable number of hits.   
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Notably, ‘cancer’ (‘bowel,’ ‘breast’) and ‘chemotherapy’ signal the disease type being 
targeted in the PIS keyword cloud, and different inflections of ‘treat’ (e.g., ‘treatment’) appear. In 
contrast, cancer is not prominently featured in the CF keyword cloud, with no reference to 
(generic/specific) treatment. Therefore, the PIS but not the CF keyword cloud appear to be cancer-
specific. Whereas ‘if,’ ‘whether,’ and ‘decide’ signal uncertainty or condition in the PIS keyword 
cloud, ‘consent,’ ‘permission,’ ‘confirm,’ and ‘understand’ in the CF keyword cloud imply 
affirmation.  
<FIGURE 2> 
Mean Flesh-Kincaid grade levels were 9.28 (SD = 1.2) for PIS and 9.75 (SD = 1.5) for CF 
compared to TASA science text corpus means of 6.78 for grades 6 to 8 and 10.35 for grades 11+. 
Figure 3 shows mean percentile scores on the five text ease dimensions for PIS, CF, and two TASA 
science text levels. For narrativity, mean PIS (48.3; SD =10.4) and CF percentile scores (43.2; SD 
=19.3) exceeded TASA science grades 6 to 8 and 11+ (31.5 and 19.7, respectively). This suggests a 
more story-like quality for the ethical documents than the science texts. In the PIS keyword cloud, 
for example, keywords contributing to this dimension include storytelling elements such as 
characters (e.g., ‘you,’ ‘patients,’ ‘doctor’), setting (e.g., ‘hospital’), and events (e.g., ‘decide,’ ‘take 
part,’ ‘surgery’). These words may be more familiar to readers than informationally dense 
explanations of scientific processes or phenomena (e.g., photosynthesis). Thus, for both ethical 
genres and particularly for PIS, narrativity positively contributed to overall text ease.  
<FIGURE 3> 
For syntactic simplicity, the mean PIS percentile (72.4; SD = 11.4) was slightly lower than 
TASA science grade 6 to 8 (76.7), whereas the CF percentile (61.7; SD = 19.4) was slightly higher 
than grade 11+ (59.8). That is, the CF is almost equivalent to advanced scientific text on this metric. 
For example, Hubbard et al.’s (2016) CF, which received the lowest score on the syntactic simplicity 
 
 
LANGUAGE DEMANDS OF INFORMED CONSENT IN TRIALS 
16 
 
dimension, featured the following numbered statement, which the patient needed to initial to indicate 
consent: ‘I understand that if consent to participate in the study is declined or terminated at any 
stage, I will enter normal post treatment follow up care.’ This 26-word, four-clause long sentence, 
which expresses the consequence of hypothetical circumstances (conditional tense), is written in 
passive voice, with no direct indication of the agent who would be declining or terminating 
participation in the study. The compound words in the noun phrase at the end of the sentence (‘post 
treatment;’ ‘follow up’) are written as separate words without hyphens in the original CF, making it 
difficult for the reader to parse that these terms are being used as adjectives attributed to the noun 
‘case,’ particularly because the word ‘treatment’ on its own is more often used as a noun and ‘up’ as 
a preposition. Primrose et al.’s (2004) CF, which is a more typical exemplar for syntactic simplicity 
and only slightly exceeds the mean wordcount (62.93), includes the statement: ‘I understand that 
sections of any of my medical notes may be looked at by responsible individuals from the study 
group or from regulatory authorities where it is relevant to my taking part in research.’ This 35-word 
sentence is also written in passive voice, contributing to its complexity. The embedded clauses 
following the word ‘by’ obscure the meaning of who would receive access to patients’ records. It is 
also unclear which sentence element the pronoun ‘it’ refers to (i.e., ‘sections of any of my medical 
notes’ accords with the plural pronoun ‘they’), underscoring the difficulty in parsing this sentence. 
The mean PIS percentile for word concreteness (25.5; SD = 11.7) was markedly lower than 
the mean for CF (55.1; SD = 18.5) and TASA science grades 6 to 8 (67.8) and 11+ (50.7). This 
suggests that a major source of PIS text difficulty relates to the use of abstract terms (i.e., not 
detectable using physical senses), including the keywords ‘treatment,’ ‘trial,’ ‘care,’ and 
‘participation.’ However, abstract concepts are not exclusively used in PIS, as Figure 2 also includes 
concrete nouns (e.g., ‘doctor,’ ‘hospital’). Low word concreteness also contributes to CF text 
difficulty, although to a lesser extent than for PIS. 
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PIS received a similar mean percentile for referential cohesion (64.9; SD = 13.3) and a higher 
value for deep cohesion (76.0; SD = 12.4) compared to TASA science grades 6 to 8 (67.8 and 55.9 
on these dimensions, respectively). This suggests that PIS were written with explicit links between 
ideas, helping the reader form meaningful connections. For example, this passage from Stein et al.’s 
(2016) PIS has high referential cohesion due to lexical and content overlap across sentences: ‘You 
will decide whether or not to continue. If you decide not to continue, your doctor will arrange for 
your future care. If you do continue, you may be asked to read a new Information Sheet. You might 
also be asked to sign a new Consent Form.’ Conversely, the mean CF referential cohesion (59.0; SD 
= 28.6) and deep cohesion (49.9; SD = 24.6) were lower than TASA grades 11+ science texts (61.8 
and 54.9, respectively), although the high standard deviations for CF are notable. One explanation 
relates to the genre of CF as a legal document comprised of declarative statements referring to 
discrete elements of trial participation expressed as isolated points, with little content overlap across 
statements. For example, CF clauses, such as ‘I agree to my GP being informed…’, ‘I agree to give 
for this project: tissue samples…’, and ‘I understand that I will not benefit financially….’ are written 
as stand-alone statements with no interlinking. Whereas there are 405 instances of the temporal 
connectives ‘then,’ ‘after,’ and ‘during’ in PIS (e.g., ‘If you are harmed due to someone’s 
negligence, then you may have grounds for a legal action’; ‘During the course of any study it is 
possible that something may go wrong’), this compares to only 19 temporal connectives in CF, with 
temporal connectives absent from 10 of the 23 CF. This translates into a lower incidence of temporal 
connectives for CF (4.3) compared to PIS (13.7), suppressing deep cohesion scores for CF.  
Next, we used a bottom-up, data-driven approach to examine the grammatical features that 
characterize the IC materials, extracting examples of language in context (McEnery & Hardie, 2012). 
To detect significantly more represented POS categories in the ethical corpora compared to BE06 
using normalized frequencies (LL), we used the same statistical cut-offs as for the keywords above. 
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Log odds (effect size) reveals the odds of the POS category occurring in the PIS or CF corpus 
compared to the odds of occurrence in BE06 (Brezina, 2018). Table 2 shows that the top key POS 
category in the PIS corpus compared to BE06 is the polysemous (ambiguous) second-person 
pronoun ‘you.’ Prototypically, ‘you’ refers to one or more addressee(s) in an interaction, but it also 
performs other functions in English, with its precise referent context-dependent (Quirk et al., 1985). 
For example, ‘you’ can also be used generically to mean ‘one,’ and the referent in this case may or 
may not include both addressee and speaker. Figure 4 shows a random sample drawn from a 
concordance―that is, a list of all occurrences of the term ‘you’ from the PIS corpus, with a few 
words shown before or after. These examples, which demonstrate how the word is used in context, 
suggest that ‘you’ was used in PIS for different reasons, most frequently to outline what may happen 
or be offered to the participant, what they, in turn, would do, and any conditions or restrictions that 
apply.  
<TABLE 2> 
<FIGURE 4> 
Approximately 25% of the instances of ‘you’ in PIS (502/2083) were immediately preceded 
by ‘if’ (a keyword). Nearly a third were immediately followed by a modal verb (675/2083), itself the 
second key POS category, with the formulaic phrase ‘if you would like’ (39/2083) the only overlap 
between these two uses of ‘you.’ ‘If’ prototypically expresses a conditional and restricts the truth 
value or certainty of a statement. Similarly, modal verbs tend to express different degrees of certainty 
or obligation. Certainty that is restricted with ‘if’ is reasonably clear to interpret (Y happening is 
predicated on X happening first), although, as a complex sentence with at least one dependent clause, 
it increases readers’ cognitive load (McNamara et al., 2014). The same is true of ‘whether’ when 
used as a conjunction, which is sixth in the key POS list. However, inferring the meaning of modal 
verbs such as ‘can,’ ‘may,’ and ‘might’ is less straightforward. These are polysemous (e.g. ‘can’ 
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expresses possibility/probability, ability, and permission) and denote variable degrees of certainty as 
well as ability and possibility, which are not fixed and, therefore, may be difficult to interpret (Quirk 
et al., 1985). These different shades of meaning are likely to substantially increase PIS language 
demands.  
The significantly higher use of modal verbs in PIS compared to the BE06 reference corpus 
implies that readers’ grasp of the range of meanings that they are able to express is important. The 
most frequently used modal verb in PIS is ‘will,’ accounting for 57% of all modal verbs 
(1414/2486). The next most frequent modal verbs were ‘may’ (380/2486), ‘can’/‘cannot’ (273/2486), 
and ‘would’ (230/2486), with some uses of ‘should,’ ‘might,’ ‘could,’ ‘must’ and a handful of 
instances of ‘shall.’ ‘Will’ is most frequently used to describe how the trial will be conducted, 
including procedures, documentation, confidentiality, results, dissemination, and treatment or test 
administration. In these instances, ‘will’ expresses the highest possible level of certainty about some 
future event (e.g., ‘you will be asked to complete a number of questionnaires,’ ‘your remaining 
samples will be destroyed’). Less certain modal verbs, such as ‘may,’ generally describe procedures 
or outcomes that may not apply to all participants or depend on certain circumstances (e.g., ‘side 
effects are listed below, but you may or may not have these’). However, ‘may,’ ‘would,’ and ‘might’ 
are also used to describe more concretely established procedures (e.g. ‘we may collect some 
information from your hospital notes or NHS [National Health Service] records’). Less certain modal 
verbs are also typically used to explain the risks of participation, and the range of modal verbs used 
in this way could be confusing. For example, modal verbs in ‘your blood pressure may also fall,’ 
‘cisplatin can affect your kidneys,’ ‘tamoxifen might also increase the risk of,’ and ‘taking part in 
this study may result in added costs to me’ express different degrees of certainty but not on a fixed, 
clearly interpretable scale. A potential participant may, therefore, have difficulty differentiating 
between risks and their likelihood of occurrence. Some PIS counteract the vagueness of modal verbs 
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(Cutting, 2007) by providing statistics alongside or instead of uncertain modal verbs (e.g., ‘between 
1 in 10 and 1 in 100 people will experience these side effects’), although interpreting such figures 
would assume a degree of numeracy on the part of the patient (Academy of Medical Sciences, 2017). 
Less certain modal verbs are also often used to describe what the objectives or benefits of the trial 
will be (e.g., ‘it is believed that covered stents may be more effective,’ ‘it may benefit others taking 
part,’ and ‘to see if people recovering from bowel cancer can also benefit’). Such hedging could 
obscure participation benefits for patients. However, other PIS do opt for more definite benefit 
statements using the modal verb ‘will,’ such as ‘the results of this research will be used by the NHS 
to decide’ and ‘this way we will be able to find out which works best.’ ‘In addition, modal verbs are 
not all equal in terms of frequency in English generally, including ‘may,’ which tends to be less 
frequent than ‘will’ (also proportionally represented in the corpora). Therefore, some modal verbs 
are both more ambiguous, and less likely to have been encountered by people for whom English is 
not a dominant language (Nation, 2013). 
The top key POS category in CF is also a pronoun—the first person ‘I’ (see Table 3). Thus, 
when PIS and CF are considered together, two different pronouns are used to denote the same 
referent, namely the participant. In fact, even within the CF corpus, both ‘I’ and ‘you’ occur with 
reference to the participant (although ‘you’ does not occur at a statistically significant level of 
frequency), which could breed confusion. In CF, ‘I’ is frequently used in word combinations such as, 
‘I am free to withdraw,’ ‘I confirm that,’ ‘I have read and understood,’ ‘I give (my) permission,’ ‘I 
agree to,’ and ‘I understand that’ (see Figure 5). Such uses account for almost 70% of the uses of ‘I’ 
(239/353). What is interesting about these phrases is their unmitigated nature. There are a few 
instances of modal verbs following ‘I,’ but these are mainly ‘will,’ which expresses high certainty, 
and a handful of instances of ‘may’ and ‘can,’ in this case denoting permission or ability rather than 
limiting certainty. In contrast to PIS, where varying degrees of certainty and conditionals 
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characterize the immediate co-text of ‘you’ (i.e., the participant being referred to), in CF, absolute 
certainty characterizes the context of the participant-referring expression ‘I.’ While the information 
that the patient is given is tentative and hedged in PIS, he/she can only choose to confirm certainty of 
understanding the conditions of the trial in CF, potentially following oral requests to clarify 
information, with the only alternative being to not complete the form and, thereby, withhold consent. 
Reconciling these two contradictory positions in which a potential signatory is being cast is likely to 
increase cognitive load and may be jarring for some, potentially deterring participation.  
<TABLE 3> 
<FIGURE 5> 
Conclusions 
This mixed methods study describes the development of the first open-access online PIS and 
CF corpora for RCTs (Isaacs et al., 2019). It demonstrates the potential of analyzing textual data 
using underutilized corpus and computational tools in trials methodology research. This 
interdisciplinary approach could lead to new ways of examining language use and textual difficulty 
in ethical documents across social science and medical domains. The results confirm previous 
findings showing that CF fail to meet recommended readability levels for public health documents 
(Eltorai et al., 2015) and extend them to PIS. Moving beyond unidimensional readability measures, 
Coh-Metrix text ease profiles reveal that for PIS, the major source of discourse-level text difficulty 
lies in low word concreteness. This poses a challenge because core IC concepts (e.g., ‘take part,’ 
‘withdraw,’ ‘treatment,’ ‘participation,’ ‘permission’) and trial design (e.g., randomization) are 
abstract and may need to be carefully constructed to cater to all patients. The linguistic dimensions 
that detract from text ease are more distributed across dimensions for CF than for PIS. CF syntactic 
simplicity and word concreteness values are slightly higher than in the advanced scientific reference 
text, whereas referential and deep cohesion scores are slightly lower. The Health Research 
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Authority’s (2019) guidelines not to ‘use the passive voice’ nor to ‘introduce more than one 
idea/point in a sentence’ for PIS should also extend to CF, as more complex sentences can heighten 
readers’ processing load (Graesser et al., 2011).  
Although appearing to render CF more difficult, a counter explanation for the low referential 
and deep cohesion scores is that these dimensions are not relevant to the CF genre due to the lack of 
overlap between ideas and absence of causal relationships. This is reflected in the overall structure of 
CF, which consists of discrete (often numbered) statements expressing different conditions of 
participation with little content overlap across statements. Future research could consider whether 
other measures/dimensions of textual difficulty are more germane while also examining 
interrelationships among the examined indices to empirically establish potential trade-offs or back 
researchers’ claims that optimized versions of IC documents are, in fact, improved on all metrics.  
At first glance, the high PIS and CF narrativity scores may appear surprising. In light of the 
composite measures that comprise the narrativity dimension, this finding can be partially explained 
by the overarching focus on individuals as characters in a story, including the extensive use of the 
pronouns ‘I’ and ‘you.’ In addition, in the two keyword clouds for both ethical genres, ‘patient(s),’ 
‘doctor,’ ‘researcher,’ ‘participant,’ ‘nurse,’ name the actors in the story, whereas ‘hospital’ and 
‘office,’ reveal the setting, underscoring the human element and setting the scene for action. This 
would positively contribute to narrativity compared to discussing scientific concepts or processes, 
particularly that refer to inanimate objects or phenomena removed from everyday lay conversation. 
Although these storyesque elements are clearly present, the narrativity algorithm is impervious to 
which concepts and, by extension, words are related to the most important elements of IC and which 
are not. For example, patients’ understanding of key concepts such as ‘treatment(s)’, ‘consent,’ 
‘withdraw,’ ‘samples,’ ‘the study,’ and ‘voluntary’ are arguably fundamental to IC, but their 
importance relative to other terms is not reflected in the percentile score. Further, some of these 
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words are polysemous and it is not clear how the algorithm deals with their semantic meaning. For 
example, it may be that ‘study’ is interpreted by the algorithm to mean a room at home where work 
can be done (as opposed to the intended meaning of a research investigation), ‘treatment’ is regarded 
as how a person is treated (as opposed to the intended meaning of medical treatment or experimental 
treatment), and ‘trial’ is assumed to be a legal trial (rather than one conducted in healthcare settings). 
The secondary meaning of these terms as they are used in IC would likely mean that the narrativity 
percentile scores are artificially inflated relative to what they should be if the algorithm took into 
account the correct, less familiar definition.  
Taken together, our analyses suggest that text difficulty involves more than word count or 
readability. For example, such measures are impervious to differences in word concreteness that 
could markedly affect the linguistic complexity of texts and, in turn, how easy they are for readers to 
process and understand (Košak-Babuder et al., 2019). Burman et al. (2003) reveal that ethics review 
committees sometimes mandate that ethical forms be rewritten if they do not achieve a certain 
readability level but that this is counterproductive, leading to lengthier documents with more textual 
errors. Overemphasizing readability at the expense of other aspects of text difficulty would seem to 
be underrepresenting this multifaceted construct, including in studies testing the efficacy of using 
reportedly optimized IC documents (Beskow et al., 2010) or best practice guidelines for writing 
ethical forms (e.g., National Institutes of Health, 2017).  
The key POS analysis reveals a fundamental contradiction in how (un)certainty is expressed 
in PIS (e.g., you + modal verb) versus CF (e.g., I + verb of affirmation + that). Although often 
operationalized as separate genres, the PIS and CF work together. They position participants in the 
contradictory position of being, in the PIS, uncertain about the intervention, conduct of the trial, or 
consequences of participation, while in the CF, requiring them to demonstrate certainty in their 
understanding, which underpins their participation decision. This raises questions about how 
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uncertainty and risk need to be communicated to potential trial participants and what this means for 
patients when they need to sign against legally binding declarative statements that confirm their 
understanding of what participation entails in CF (Nishimura et al., 2013). This issue is particularly 
pertinent when the stakes for participation are high, as is often the case in cancer trials (e.g., invasive 
treatments, difficult side-effects, intervention may or may not prolong lives; Davies et al., 2015).  
A 2017 Academy of Medical Sciences report argues for redressing the balance in 
communicating risks and benefits in patient information leaflets accompanying medication, claiming 
that risks tend to be overemphasized and potential benefits insufficiently highlighted. Notably, trials 
are a different context (e.g., participant recruitment pressures), although there are some parallels with 
drug leaflets (e.g., lay audience). The use of hedging—that is, vague, tentative language using less 
certain modal verbs—could dissuade patients from participating. Being more definite about benefits 
of the study using the modal verb ‘will’ could mitigate this. However, doing so may be misleading 
when there is uncertainty about how individual patients will react to an intervention (e.g., group 
aggregate effects cannot predict individual outcomes; Academy of Medical Sciences), unless the 
benefit being emphasized is about altruistic good in improving knowledge for the benefit of science, 
society, or others with the disease rather than the effect of the treatment (whichever is assigned) on 
the individual. That is, the onus is on the researchers to present the benefits of trial participation as 
truthfully as possible, which could mean not framing benefits in definite terms, although this could 
lead to prospective participants’ lower comprehension of the degree of risk involved. There are also 
instances of researchers attempting to minimise risk in PIS using ‘will’ or the simple present to 
convey certainty (e.g., ‘this does entail some risk, but in this case the benefits outweigh any such 
risk;’ ‘there will be no additional radiation risk from you taking part in the trial and you are not likely 
to suffer’). In most cases, risk level is written in vague or relativistic terms, making decisions about 
participation based on risk assessment difficult. It may be that quantifying risk using simple statistics 
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in context is not always possible, and patients’ ability to interpret them may also be an issue. We 
wish to advance the idea of using corpus extracts (e.g., context-laden concordance lines) to gauge 
patient preference for the way that concepts such as risk/benefit or randomization are communicated 
in future research, in conjunction with different measures of their understanding. This would build 
the evidence base for optimizing how IC documents are crafted, buttressing language-based best 
practice recommendations in ways that accord with patients’ perspectives (e.g., Health Research 
Authority, 2019). 
Limitations 
This study has several limitations. First, our corpora only include a small number of publicly 
available materials located through online database searches so that we could make the resulting 
corpora available open access. Exemplars or extracts from such open access IC repositories could be 
randomized and embedded within a larger host trial to see which wording is most effective (Treweek 
et al., 2018a). However, increasing corpora size is essential in future research so that more robust 
characterizations of the language of IC can be obtained. This could enable investigations of trends 
over time, comparisons across countries/regions, and differences across medical conditions, for 
example. Second, we did not validate Coh-Metrix easbility dimensions, which were robust in 
determining differences in previous research (Graesser et al., 2011), for use with the ethical genres in 
this study. Future research could probe whether other measures are more appropriate for 
characterizing textual differences in ethical documents. Third, to inform the direction of our study, 
we ran patient and public involvement sessions with six volunteers (cancer patients, carers, policy 
reviewers) who guided us in an advisory capacity. However, their voices and those of other 
stakeholders (e.g., recruiters, ethical reviewers) are not directly reflected in this paper. Fourth, 
although assumptions about patient understanding underpin this study, this construct was not 
examined. Future research could investigate objective and subjective measures of patient 
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understanding in conjunction with textual analyses (see Gillies et al., 2018). Fifth, the comparator 
corpora used here are not specific to health or legal domains, nor to the language of research ethics. 
Future research could use other reference samples, including medical or legal corpora. Next, 
although six PIS contained nontextual information, we excluded these data and solely examined 
textual information in our analyses. Future research could employ multimodal analysis to examine 
all sources of nontextual information (e.g., flowcharts, videos), potentially in conjunction with 
textual analyses of IC conversations, to capture all forms of communication provision available to 
prospective participants (Wade et al., 2017). Finally, proposing concrete best practice guidelines for 
crafting IC documents would be premature based on the limited evidence generated in this study, 
including because patient representatives were not directly consulted. However, there are steps that 
would enable us to do so in an evidence-based way in future research. As per the above, we would 
suggest drawing on examples from larger-scale corpora to elicit different indicators of prospective 
participants’ understanding of alternative framings of similar concepts. This would need to be paired 
with research on the best cocktail of linguistic measures (including discourse-level measures) that 
capture key elements of textual quality for information that is deemed essential for IC, given 
community or stakeholder consensus of what those core elements are. Taken together, this could 
begin to provide an evidential basis for genuinely improving information provision in PIS and CF, 
thereby making participants’ decision-making truly more informed. Clearly, there is fertile ground 
for applying and extending the methods presented here to better understand the linguistic facets of 
textual difficulty in research ethics communication. 
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Table 1. Characteristics of 28 RCTs whose ethical materials were included in the corpora. 
 
Studya 
Start 
date 
Type(s) of 
cancer/tumor 
Intervention Cancer 
screening 
Materials 
obtained Data source 
Barr (2009) 2009 Oesophageal Clinical Yes PIS; CF NIHR protocol 
Bayman (2016) 2012 Lung Clinical  PIS; CF Supplementary material to 
protocol 
Clive (2015) 2011 Lung Clinical  PIS; CF Supplementary material to 
protocol 
Davies (2015) 2015 Any type Clinical  PIS Supplementary material to 
protocol 
Davies (2013) 1995 Breast Clinical; 
behavioral 
 
PIS; CF 
Supplementary material to 
results 
Dunn (2013) 2013 Breast Clinical  PIS; CF Trial website 
Faivre-Finn 
(2016) 
2005 Lung Clinical  
PIS; CF 
Supplementary material to 
protocol 
Field (2016) 2014 Lung Clinical  PIS Trial website 
Foxtrot (2012) 2007 Bowel Clinical  PIS; CF Trial website 
Glazener (2011) 2004 Prostate Behavioral; 
educational 
 PIS; CF 
NIHR final report 
Halligan (2015) 2004 Bowel Clinical; 
behavioral 
 PIS; CF 
NIHR final report 
Hamdy (2015) 2015 Prostate Clinical  PIS Trial website 
Hill (2016) 2017 Bowel Clinical  PIS ISRCTN Registry 
Hubbard (2016) 2013 Bowel Behavioral; 
educational 
 PIS; CF 
NIHR final report 
James (2016) 2007 Prostate Clinical  PIS; CF NIHR final report 
Jenkinson (2014) 2014 Meningioma 
(brain tumour) 
Clinical  PIS; CF 
Trial website 
Kitchener (2014) 2001 Cervical Clinical Yes PIS; CF NIHR final report 
Kitchener (2016) 2011 Cervical Behavioral; 
educational 
Yes PIS; CF 
NIHR final report 
Koutoukidis 
(2016) 
2015 Uterine Behavioral; 
educational 
 
CF 
Supplementary material to 
protocol 
Langley (2014) 2015 Breast; colorectal; 
gastrooesophageal 
Clinical  PIS; CF 
NIHR protocol 
Maughan (2013) 2013 Prostate Clinical  PIS; CF NIHR protocol 
Mulvenna (2012) 2007 Bowel Clinical  PIS; CF Trial website with 
protocol 
Primrose (2004) 2004 Lung Clinical; 
educational 
 PIS; CF NIHR final report 
Stein (2016) 2012 Bowel Clinical  PIS; CF NIHR final report 
Turnbull (2010) 2001 Breast Clinical  PIS; CF NIHR final report 
Warde (2012) 1995 Breast Clinical  PIS; CF Supplementary material to 
protocol 
Williams (2011) 2003 Breast Clinical  PIS; CF NIHR final report 
Woods (2016) 2015 Prostate Behavioral  PIS Trial website via ISRCTN 
 
aFirst author (year)  
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Table 2. Key POS categories for PIS corpus. 
 
POS tag 
 
POS category descriptor 
 
Frequency 
in PIS 
Frequency in 
BE06 Log-
likelihood 
 
Log 
ratio 
 
Examples 
 Raw 
per 
1000 Raw 
per 
1000 
PPY 2nd person personal pronoun (you) 2085 3.56 4796 0.52 3929.9 2.79 You 
VM 
modal auxiliary (can, will, would, 
etc.) 2486 4.25 12086 1.3 2214.23 1.71 
will, can, 
may 
VBI be, infinitive (It will be...) 1069 1.83 5297 0.57 927.28 1.68 be 
DD 
determiner (capable of pronominal 
function) (e.g., any, some) 533 0.91 2440 0.26 514.41 1.79 any, some 
CSW31 whether or_not 49 0.08 23 0 189.58 5.08 
whether 
or not 
CSW whether (conjunction) 119 0.2 423 0.05 153.76 2.16 whether, if 
NN121 follow_up as singular noun 39 0.07 35 0 122.36 4.15 follow up 
VDN done 49 0.08 243 0.03 42.45 1.68 done 
 
Note. The POS tag in the first column are labels or codes used in Wmatrix’s automated tagging system, which 
automatically assigns a grammatical category (POS) to keywords in the corpus. The ‘Category descriptor’ in column 2 
elaborates what each POS tag refer to. 
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Table 3. Key POS categories for CF corpus. 
 
POS tag 
 
POS category descriptor 
 
Frequency 
in PIS 
Frequency in 
BE06 Log-
likelihood 
 
Log 
ratio 
 
Examples 
 Raw 
per 
1000 Raw 
per 
1000 
PPIS1 1st person singular pronoun (I) 353 4.55 7717 0.83 613.3 2.45 I 
CST that (conjunction) 180 2.32 7292 0.78 150.17 1.56 that 
VBI be, infinitive (It will be...) 142 1.83 5297 0.57 134.03 1.68 be 
DD 
determiner (capable of pronominal 
function) (e.g., any, some) 84 1.08 2440 0.26 109.15 2.04 any, some 
VH0 have, base form (finite) 77 0.99 2809 0.3 75.01 1.72 have 
VHN had (past participle) 25 0.32 304 0.03 67.86 3.3 had 
VBM Am 34 0.44 821 0.09 53.74 2.31 am 
VBG Being 31 0.4 897 0.1 40.46 2.05 being 
 
Note. The POS tag in the first column are labels or codes used in Wmatrix’s automated tagging system, which 
automatically assigns a grammatical category (POS) to keywords in the corpus. The ‘Category descriptor’ in column 2 
elaborates what each POS tag refer to. 
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Figure 1. PRISMA diagram summarizing the selection of eligible materials for corpora building.  
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Figure 2. Keyword cloud from PIS corpus (above) and CF corpus (below). 
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Figure 3. Percentile scores for five text ease components for the PIS corpus, CF corpus, and TASA 
science texts grades 6 to 8 and 11+. 
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Figure 4. Random sample of 20 concordance lines for the pronoun ‘you’ in PIS corpus. 
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Figure 5. Random sample of 20 concordance lines for the pronoun ‘I’ in CF corpus. 
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Electronic Supplementary Material 1 
Search strategy and eligibility information by online platform 
NIHR Journals Library 
URL: https://www.journalslibrary.nihr.ac.uk  
 
We included all RCTs categorised as ‘Primary Research’ for the following funding streams: Health 
Technology Assessment, Health Services and Delivery Research, Public Health Research, 
Programme Grants for Applied Research, and Efficacy and Mechanism Evaluation. 
 
Search strategy: HRCS Category ‘Cancer’ 
 
Europe PMC 
URL: https://europepmc.org  
 
We included all studies funded by Cancer Research UK, Prostate Cancer UK, Academy of Medical 
Sciences, Breast Cancer Now, Breast Cancer Campaign, and Dunhill Medical Trust. 
 
Search strategy: 
(ABSTRACT:"cancer") AND (GRANT_AGENCY:"Cancer Research UK" OR 
GRANT_AGENCY:"Academy of Medical Sciences (AMS)" OR GRANT_AGENCY:"Breast 
Cancer Now" OR GRANT_AGENCY:"Breast Cancer Campaign" OR GRANT_AGENCY:"The 
Dunhill Medical Trust") AND SRC:med AND HAS_FT:y AND (PUB_TYPE:"Randomized 
Controlled Trial") AND (LANG:"eng" OR LANG:"en" OR LANG:"us") 
 
Research for Patient Benefit 
URL: https://www.nihr.ac.uk/research-and-impact/research/nihr-studies/research-for-patient-
benefit.htm 
 
Search strategy: UKCRC Category ‘Cancer’ 
 
Medical Research Council 
URL: https://www.mrc.ac.uk/research/funded-research 
 
We included all funded RCTs that conformed with our inclusion parameters. 
 
Search strategy: HRCS Category ‘Cancer’  
 
Medline and Embase 
URL: http://ovidsp.ovid.com  
 
Search strategy:  
‘RCT* AND cancer AND (consent form) AND (information sheet) AND UK’ 
 
This search produced 9009 publications from potentially eligible studies. From these results, we 
manually reviewed the first 5% (450), of which 3.8% (17 out of 450) were studies that had not 
already been identified. However, no new PIS or CF were located for these 17 studies for inclusion 
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in our corpora. On that basis, we decided a complete review of the full 9009 was unlikely to 
substantially result in the identification of new data and searching was ceased. 
 
Cochrane Central Register of Controlled Trials  
URL: http://www.cochranelibrary.com/about/central-landing-page.html  
 
Search strategy: RCT* AND cancer AND UK 
 
Google Scholar 
URL: https://scholar.google.co.uk 
 
Search strategy: ‘informed consent’ AND ‘comprehension’ AND ‘trials’ AND ‘cancer’ 
 
We restricted our search to RCTs published between 2006 and 2017 and manually reviewed the first 
100 entries to check for data saturation. This search did not lead to any new CF or PIS for inclusion 
in our corpora. 
 
ORRCA database 
URL: http://www.orrca.org.uk 
 
Search strategy: Searched all abstracts grouped under the health area ‘cancer’  
 
We ordered the resulting studies by year to manually review those published since 2006 as a final 
check for data saturation. This search did not result in any new CF or PIS for inclusion in our 
corpora. 
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Electronic Supplementary Material 2 
Procedures for data cleaning and archiving 
To prepare the PIS and CF corpora for analysis and digital archiving, the original files were 
converted to .txt files. Text recognition tools or manually typing text was used in rare instances when 
the words could not be automatically detected. We then cleaned the data using the following steps: 
- Spacing irregularities corrected 
- Hyphens splitting single words over two lines or between two words removed (e.g., ‘once-
daily’ changed to ‘once daily’) 
- Text appearing on the forms but not presented to patients deleted (e.g., publication footnotes)  
- Typos and grammatical errors in the original documents and introduced by the conversion 
process corrected (e.g., ‘principle’ changed to ‘principal’; ‘satified’ to ‘satisfied’; ‘asprin’ to 
‘aspirin’; ‘lead’ to ‘led’; ‘you family’ to ‘your family’) 
- Nontextual information deleted and ‘TABLE’, ‘DIAGRAM’, or ‘IMAGE’ inserted to 
demarcate where the original information had appeared   
- Researchers’ names, institutional information, and contact details removed; however, RCT 
name, acronym, and website retained 
 
 
 
